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Hendra virus is a highly pathogenic zoonotic paramyxovirus in the genusHenipavirus. Thirty-nine outbreaks of Hendra virus
have been reported since its initial identification in Queensland, Australia, resulting in seven human infections and four fatali-
ties. Little is known about cellular host factors impacting Hendra virus replication. In this work, we demonstrate that Hendra
virus makes use of a microRNA (miRNA) designated miR-146a, an NF-B-responsive miRNA upregulated by several innate im-
mune ligands, to favor its replication. miR-146a is elevated in the blood of ferrets and horses infected with Hendra virus and is
upregulated by Hendra virus in human cells in vitro. Blocking miR-146a reduces Hendra virus replication in vitro, suggesting a
role for this miRNA in Hendra virus replication. In silico analysis of miR-146a targets identified ring finger protein (RNF)11, a
member of the A20 ubiquitin editing complex that negatively regulates NF-B activity, as a novel component of Hendra virus
replication. RNA interference-mediated silencing of RNF11 promotes Hendra virus replication in vitro, suggesting that in-
creased NF-B activity aids Hendra virus replication. Furthermore, overexpression of the IB superrepressor inhibits Hendra
virus replication. These studies are the first to demonstrate a host miRNA response to Hendra virus infection and suggest an im-
portant role for host miRNAs in Hendra virus disease.
Hendra virus (HeV)was first identified as the causative agent inan outbreak of severe respiratory disease at a horse stable in
Hendra, a suburb of Brisbane, Queensland, Australia, in Septem-
ber 1994 (1). This initial outbreak resulted in the death of 13
horses and 1 human. It was subsequently determined that Hendra
virus is carried by bats of the genus Pteropus (2) with the virus
transmitted to horses likely via excretory contamination of the
equine environment. Since 1994, 39 outbreaks of Hendra virus
have occurred, all confined toAustralia, with 18 of those occurring
in 2011 (3). Furthermore, 2011 marked the first time outside a
laboratory setting that an animal other than a horse or a bat was
associated with Hendra virus infection, with a companion dog
from an outbreak property testing antibody positive for Hendra
virus. The highmortality rate ofHendra virus infection in humans
(7 known infections with 4 fatalities; mortality rate, 57%) demon-
strates the threat of increasing outbreak events to human health
and emphasizes a requirement to further understand determi-
nants of Hendra virus disease.
MicroRNAs (miRNAs) are a class of noncodingRNAs that play
a critical role in the regulation of most biological processes (re-
viewed in reference 4). miRNAs were first identified in Caeno-
rhabditis elegans (5), and it is estimated that the human genome
contains more than 700 miRNAs, with each miRNA potentially
capable of regulating many, perhaps hundreds of, target mRNAs.
The production of miRNAs requires several processing steps: pri-
mary miRNAs (pri-miRNAs) are first cleaved by the RNase
Drosha to produce precursor miRNAs (pre-miRNAs), which in
turn are cleaved by the RNase Dicer to produce mature, single-
stranded miRNAs (6, 7). The binding of miRNAs to target gene
mRNA can lead to the degradation, the suppression, or even the
upregulation of target mRNA levels. Interestingly, recent studies
have identified both host- and virus-encoded miRNAs as critical
elements regulating virus replication. For example, human miR-
122 is an essential component of the biology of hepatitis C virus
replication (8). Therapeutic blocking of miR-122 suppresses hep-
atitis C viremia in nonhuman primates (9).
Given the breadth of miRNA-mediated regulation of infection
and immunity in mammals (reviewed in reference 10), the role of
host miRNAs in Hendra virus infection is of significant interest.
miR-146a is anNF-B-responsivemiRNA that is considered a key
regulator of inflammation (11). miR-146a is upregulated by stim-
ulators of the innate immune response, such as lipopolysaccharide
(LPS) and tumor necrosis factor alpha (TNF-) (12), and by sev-
eral viruses, including vesicular stomatitis virus (VSV) and Ep-
stein-Barr virus (13, 14). Validated and well-studied target genes
of miR-146a include interleukin 1R (IL-1R)-associated kinases
(IRAK) and the TNF receptor-associated factor 6 (TRAF6), mol-
ecules directly involved in Toll-like receptor (TLR) signaling,
NF-Bactivation, anddownstreamproinflammatory chemokine/
cytokine expression (12).
In this study, we have investigated miR-146a induction in
Hendra virus infections in vivo and in vitro. Our results provide
insight into the previously unappreciated role of host miRNAs in
Hendra virus replication and suggest an important role for miR-
146a in Hendra virus disease.
MATERIALS AND METHODS
Cells. HeLa cells (ATCC CCL-2) were maintained in growth medium
(Eagle’s minimal essential medium [EMEM] supplemented with 10%
[vol/vol] fetal calf serum [FCS], 10 mM HEPES, 2 mM L-glutamine, 100
U/ml penicillin, and 100 g/ml streptomycin). African green monkey
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kidney epithelial Vero cells (ATCC CRL-81) and HEK 293T cells (ATCC
CRL-11268) were maintained in Dulbecco modified Eagle medium
(DMEM) supplementedwith 10% (vol/vol) FCS, 100U/ml penicillin, and
100 g/ml streptomycin. All cells were incubated at 37°C under a 5%
CO2/95% air atmosphere.
Reagents. Short interfering RNAS (siRNAs) used in this study were
siGENOME siRNA reagents purchased from Dharmacon RNAi Technolo-
gies (Lafayette, CO). The negative-control siRNA (siNEG) (Non-Targeting
siRNA No. 1) was also purchased from Dharmacon. Cells were incubated
with inhibitors (antagomirs) specific to mir-146-a (AsAsCCCAUGGAAUU
CAGUUCsUsCsAs-Chol [amo146a]) or a negative-control antagomir (Us
AsUUUACCCUUUACUUGUCsUsAsUs-Chol [amoNEG]) purchased
fromGeneWorks (Adelaide, Australia); s refers to phosphorothioate link-
ages. A, C,G, andU refer to 2=OMeA,C,G, andU, respectively. Poly(I·C)
was purchased from Invivogen (San Diego, CA).
Purification of RNA from Hendra virus animal trials, reverse tran-
scription, and quantitative real-time PCR. Male ferrets (aged 12 to 18
months) and three adult mares were infected with Hendra virus as part of
studies described previously (15, 16). Whole-blood samples were col-
lected in EDTA on the indicated days postinfection. RNA was purified
using the RNeasy RNA purification kit from Qiagen (Doncaster, Austra-
lia) according to the manufacturer’s instructions and stored at 80°C.
RNA samples (200 ng) were treated with RNase-free DNase (Promega,
Madison,WI) according to themanufacturer’s instructions. FormiRNA-
specific quantitative real-time PCR (qRT-PCR), sample polyadenylation
was performed prior to cDNA synthesis by incubating RNA (200 ng)
with 1 U poly(A) polymerase (Affymetrix, Santa Clara, CA), 0.5 nM rATP
(Ambion, Carlsbad, CA) in 1 poly(A) polymerase buffer (InVitro Tech-
nologies) at 37°C for 30 min and then at 95°C for 5 min. cDNA synthesis
was performed using Superscript III reverse transcriptase (Invitrogen,
Carlsbad, CA) according to the manufacturer’s guidelines. For miRNA
cDNA synthesis, a modified oligo(dT) primer (miR-PTA) was used as
described previously (17). qRT-PCR was performed using Sybr green
(Applied Biosystems, Foster City, CA) on an ABI Prism 7700 sequence
detection system (Applied Biosystems). PCR cycling for gene detection
was at 95°C for 10min, followed by 40 cycles of 95°C for 15 s and 60°C for
1min. PCR cycling formiRNA detection was at 95°C for 10min, followed
by 40 cycles of 95°C for 15 s, 57°C for 30 s, and 72°C for 30 s. A melting
curve analysis was performed to eliminate primer-dimer artifacts and to
verify the specificity of the assay. For gene expression and in vivomiRNA
expression, data were analyzed using theCTmethod andwere normal-
ized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for gene
detection and 5S RNA for miRNAs. For in vitro detection of miR-146a,
copies of miR-146a per cell were determined by generating a standard
curve with synthetic miR-146a and using a defined amount of RNA from
cells to calculate copies of miR-146 per pg of RNA as described previously
(18, 19). Primers were ordered from GeneWorks. Primer sequences used
in this study are shown in Table 1. Probes used to detect the Hendra virus
P gene have been described (20).
Infection of cells with Hendra virus and purification of RNA.HeLa
cellswere seeded in24-well plates (8104 cells/well) in growthmedium.The
following day, cells were infectedwithHendra virus (Hendra virus/Australia/
Horse/1994/Hendra) with amultiplicity of infection (MOI) of 1 for the indi-
cated time points. RNA was harvested using Tri-reagent (Sigma, St. Louis,
MO) according to the manufacturer’s instructions. One microgram of ex-
tracted RNA was treated with DNase (Promega, Madison, WI) according to
the manufacturer’s instructions. Preparation of samples for RT-PCR and
qRT-PCR and subsequent analysis was performed as described above.
miFINDER miRNA PCR arrays. HeLa cells were infected with Hen-
dra virus as described above. RNAwas harvested using protocols from the
RNeasyMini RNA purification kit protocol and subsequently the RNeasy
MinElute Cleanup Kit protocol (Qiagen). Levels of 88 abundant, well-
characterized miRNAs were quantified using an RT2 miFINDER miRNA
PCR array system (SABiosciences-Qiagen) according to the manufactur-
er’s instructions.
Transfections.HeLa cells were seeded in 24-well plates (8 104 cells/
well) in growth medium. The following day, cells were transfected with
siRNAs (40 nM) or plasmidDNA (500 ng/well) using Lipofectamine 2000
(Invitrogen) according to themanufacturer’s guidelines in antibiotic-free
medium.
TCID50 analysis. For 50% tissue culture infective dose (TCID50) anal-
ysis, 10-fold dilutions of tissue culture supernatants were made in me-
dium and Vero cells added (5 104 cells/well) in a 96-well tissue culture.
Plates were incubated for 3 days at 37°C and 5% CO2 and scored for
cytopathic effect. The infectious titer was calculated by the method of
Reed and Muench (21).
3= UTR reporter assay. 3= untranslated region (UTR) reporter assays
were performed as described previously (22). Briefly,HEK293T cells were
transfected in suspensionwith 200ng of 3=UTRRenilla and 15ng of firefly
luciferase control constructs in 6-well tissue culture plates (3 106 cells/
well). Then, 6 h later, the cells were collected from the 6 wells with trypsin,
transfected further with each individual synthetic miRNA (10 nM), and
seeded into 96-well plates (1 105 cells/well). Cells were incubated for 20 h
before lysis, and firefly/Renilla assays using the Dual Glo luciferase assay sys-
tem (Promega) were performed according to the manufacturer’s guidelines.
CloningofRNF11.Human ringfinger protein 11 (RNF11)was cloned
fromcDNAof unstimulatedHeLa cells using theGatewayRecombination
Cloning Technology (Invitrogen) according to the manufacturer’s in-
structions. Primer sequences for wild-type RNF 11 were as follows: for-
ward, ATGGGGAACTGCCTCAAATC; reverse, TCAATTAGTCTCATA
GGATGAAAGCAG.
Cell viability. Cells transfected in a 96-well plate with 40 nM siRNAs
were fixed 72 h posttransfection with 4% paraformaldehyde. Cell nuclei
were then stained using 4=,6-diamidino-2-phenylindole (DAPI) nuclei
stain (Invitrogen), and the number of viable nuclei per treatment group
was quantitated using the CellInsight Personal Cell Imager (Thermo Sci-
entific, Waltham, MA).
Inhibition of NF-B activity. The pCMV-MAD-3 expression plas-
mid, in the absence or presence of the IBa suppressor (23) (a kind gift of
the laboratory of Michael Karin, The University of California at San Di-
TABLE 1 qRT-PCR primers used in this studya
Target Primer Sequence (5= to 3=)
Accession
no.
RIG-I F GAAGACCCTGGACCCTACCT AK125989
R GGCCCTTGTTGTTTTTCTCA
MDA5 F AGCTGACACTTCCTTCTGCC BC111750
R GGGGCATGGAGAATAACTCA
IFN-1 F CAGGAGAGCAATTTGGAGGA BC096153
R CTTTCGAAGCCTTTGCTCTG
IRAK1 F CTTCTCAAAGCCACTCCAGC DQ054788
R GAGACCTTGGCTGGTCAGAG
IRAK2 F TGGAATGGGACACCTGATTT AJ496794
R GCAACTTGTGGACCTCCTGT
TRAF6 F GCCACACAGCAGTCACTTTC DA855021
R TCCCGCGCACTAGAAC
GAPDH F AGGTCGGTGTGAACGGATTTG BQ187062
R TGTAGACCATGTAGTTGAGGTCA
miR-146a N/A GCGTGAGAACTGAATTCCATGGG 406938
5S RNA N/A TGGGAATACCGGGTGCTGT N/A
PAM URP N/A GAGGCGAGCACAGAATTAATACGAC N/A
a N/A, not applicable.
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ego) was transfected into HeLa cells (1.6 g/ml) seeded in 24-well plates
using Lipofectamine 2000 according to the manufacturer’s guidelines. At
24 h posttransfection, cells were infected with the indicatedMOIs of Hen-
dra virus. Alternatively, cells were incubated with chemical compound
inhibitors of NF-B activity, Bay11-0782 or MG-132 (Invivogen, San Di-
ego, CA), for 1 h prior to Hendra virus infection at the indicated MOIs.
Measurement of NF-B activity. HeLa cells were seeded at 4  104
cells/well in 24-well plates and transfected with the NF-B cis-reporting
plasmid expressing firefly luciferase (Agilent Technologies, Santa Clara,
CA) together with a Renilla luciferase control plasmid (400 ng/plasmid/
well). Transfections were done using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s guidelines. At 24 h later, cells were trans-
fected with a negative-control miRNA mimic or an miR-146a-specific
mimic (final concentration, 200 nM; Dharmacon) using Lipofectamine
2000. NF-B activity was assayed 24 h later using a dual-luciferase assay
kit (Promega).
Statistics. The difference between two groups was statistically ana-
lyzed by a two-tailed Student’s t test. A P value of 	0.05 was considered
significant. All data points are the average of triplicates, with error bars
representing standard deviations. All data are representative of results
from at least 2 separate experiments.
RESULTS
Increases inbloodmiR-146a levels aredetected inHendra infec-
tion in vivo. We examined levels of miR-146a in whole blood
collected from Hendra virus infection studies involving ferrets (a
human model for viral respiratory diseases, including henipavi-
ruses [16, 24]) and horses. In the ferret model we observed an
increase in miR-146a levels at days 6, 8, and 9 postexposure com-
pared with levels in day 0 samples (Fig. 1A). Likewise, we detected
significantly higher levels of miR-146a levels in peripheral blood
taken from horses exposed to Hendra virus as part of a horse
challenge study (15). Increases in miR-146a were detected in the
horse on day 1 postchallenge, although the Hendra virus genome
was not detected until day 5 postchallenge (Fig. 1B). Maximal
increases in miR-146a levels were observed day 3 postexposure.
Interestingly, for both ferret and horse samples, increases in miR-
146awere detected several days before the detection of theHendra
virus genome.
Hendra virus induces miR-146a in vitro via RIG-I. To assess
the role of miR-146a induction during Hendra virus replication,
we next investigated whether miR-146a induction could be repli-
cated in an in vitro model of Hendra viral infection. The human
cervix carcinoma cell line, HeLa, supports both Hendra virus rep-
lication and RNA interference (RNAi)-mediated gene silencing
(C. Stewart andG.Marsh, unpublished observations), providing a
model cell to assess miR-146a induction in human cells. A signif-
icant increase in miR-146a levels was observed in HeLa cells in-
fected with Hendra virus 3 h postinfection, with a 60-fold in-
duction observed 8 h postinfection compared to levels in
uninfected HeLa cells (Fig. 2A). A relative decrease in miR-146a
levels was observed at 24 h.
To investigate other miRNAs regulated by HeV infection in
vitro, HeLa cells were infected for 0, 3, 8, and 24 h, at which time
small RNAs were purified and levels of 88 miRNAs quantified
using a RT2 miFINDERmiRNA PCR array system. In addition to
miR-146a, we identified 8 miRNAs differentially regulated by
HeV in HeLa cells (Table 2).
The induction ofmiR-146a by VSV requires the cytosolic RNA
helicase RIG-I (14). To determine the host receptor for miR-146a
during Hendra virus infection, short interfering (si)RNAs were
transfected into HeLa cells to reduce expression of RIG-I and the
related helicase MDA5. A greater than 85% reduction in expres-
sion levels of these genes was observed 48 h posttransfection with
siRNAs (Fig. 2B). When cells with reduced expression levels of
MDA5 or RIG-I were infected with Hendra virus for 8 h, miR-
146a induction was reduced significantly in cells with reduced
RIG-I, compared to cells transfected with the siNEG negative-
control siRNA (Fig. 2C). miR-146a induction levels were compa-
rable in cells transfectedwith siNEG and cells with reducedMDA5
levels (Fig. 2C).
The Hendra virus genome has 6 genes expressing 9 proteins,
with RNA editing generating multiple proteins (P, V, or W) from
the P gene (25). To determine whether miR-146a expression is
upregulated by a particular gene or gene product of Hendra virus,
individual Hendra virus genes were transfected into HeLa cells,
with miR-146a levels measured 24 h posttransfection by qRT-
PCR.Asignificant inductionofmiR-146awasobserved incells trans-
fectedwithV(Fig. 2D),while a smallmiR-146aupregulationwas also
observed in cells transfected with L. Interestingly, V did not upregu-
late miR-146a to the same extent as whole Hendra virus (Fig. 2A).
Also of interest, the induction ofmiR-146a byVwas significantly not
altered by the silencing of RIG-I (Fig. 2E). Collectively, these findings
establish that miR-146a is induced as part of the cellular antiviral
response to Hendra virus following RIG-I activation.
miR-146a promotes Hendra virus replication. To determine
the impact ofmiR-146a induction onHendra virus replication,we
subsequently tested the effect of blocking miR-146a on Hendra
virus replication in HeLa cells. First, it was established that an
miR-146a-specific inhibitor, but not a negative-control inhibitor,
blocked miR-146a induction in HeLa cells transfected with
poly(I·C), a double-stranded RNA mimic that, when introduced
into the cell cytoplasm, activates RIG-I (26) (Fig. 3A). In accord
with this, the miR-146a-specific inhibitor, but not the negative-
FIG 1 Hendra virus induces miR-146a in vivo. qRT-PCR measurements of
miR-146a (white bars) and Hendra virus genome (black bars) in the RNA
purified from the whole blood of ferrets (A) (n 
 3) and horses (B) (n 
 3)
infected with Hendra virus. *, P	 0.05 compared to day zero samples.
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control inhibitor, blocked miR-146a induction caused by Hendra
virus infection (Fig. 3B). At multiplicities of infection (MOIs) of
0.01 and 0.1, Hendra virus replicationwas significantly reduced in
cells treated with the miR-146a inhibitor but not in cells treated
with the negative-control inhibitor (Fig. 3C). At a higher MOI of
Hendra virus (MOI, 1), there was no significant difference in virus
titers between control cells and cells with blocked miR-146a. The
miR-146a specific inhibitor also significantly reduced cellular vi-
rus levels from a 24-h infection with Hendra virus (MOI, 0.1), as
measured by qRT-PCR (Fig. 3D). These data suggest that miR-
146a induction contributes to Hendra replication.
Modulating miR-146a target gene RNF11 promotes Hendra
virus replication in vitro. To characterize the molecular compo-
nents of miR-146a activity facilitating Hendra virus replication,
we next studied whether known targets of miR-146a contributed
to Hendra replication. Well-characterized genes targeted by miR-
146a for degradation include three members of the type I inter-
feron (IFN) antiviral immune response pathway: IRAK1, IRAK2,
and TRAF6 (12, 14).We used short interfering (si)RNAs to exam-
ine the effect of specific target gene downregulation on Hendra
virus replication. While siRNAs would be expected to downregu-
late a target gene to a greater extent than anmiRNA, this approach
has been used previously to study the impact of miRNA target
gene downregulation on a biological process (14, 22). RNA inter-
ference (RNAi)-based downregulation of IRAK2 and TRAF6 sig-
nificantly reduced Hendra virus replication, while IRAK1 RNAi
did not have any effect (Fig. 4A and B). These results were coun-
terintuitive and suggested that IRAK2 and TRAF6, while being
FIG 2 Hendra virus induces miR-146a in vitro via RIG-I (A) miR-146a levels in HeLa cells infected with Hendra virus (MOI, 0.1). *, P	 0.05 compared to time
zero samples. (B) MDA5 and RIG-I mRNA levels in HeLa cells measured 48 h posttransfection with siRNAs (40 nM). **, P	 0.01. (C) miR-146a levels in HeLa
cells transfected for 48 h with siRNAs (40 nM), followed by 8 h of infection with Hendra virus (MOI, 0.1). **, P	 0.01; N.S., not significant. (D)miR-146a levels
in HeLa cells 24 h posttransfection with Hendra virus genes. Mock refers to untreated cells. Lipid refers to cells treated with transfection reagent only. *, P	 0.05
compared to mock samples. (E) miR-146a levels in HeLa cells transfected for 48 h with 40 nM siRNAs, followed by 24 h transfection with V.
TABLE 2 miRNAs differentially regulated by HeV infection in HeLa
cells
miRNA
Fold induction (P value)
3 h 8 h 24 h
mir-151-5p 3.65 (0.042) 1.91 (0.34) 3.74 (0.309)
mir-128 2.22 (0.048) 1.51 (0.53) 1.95 (0.13)
mir-140-3p 2.14 (0.051) 1.43 (0.39) 1.17 (0.73)
mir-100 2.06 (0.066) 5.71 (0.142) 13.4 (0.11)
mir-28-3p 3.05 (0.064) 1.35 (0.53) 1.47 (0.397)
mir-302c 1.31 (0.96) 1.71 (0.397) 5.38 (0.023)
mir-150 1.83 (0.73) 3.13 (0.4) 5.83 (0.024)
mir-142-3p 2.29 (0.19) 2.04 (0.379) 9.67 (0.08)
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repressed following Hendra virus-driven miR-146a induction,
significantly contributed to Hendra virus replication.
NF-Bparticipates in the induction of the interferon responses
and affects cell survival. We therefore measured the effect of
RNAi-mediated knockdown of IRAK1, IRAK2, and TRAF6 on
IFN- production and cell survival. RNAi-mediated silencing of
these genes did not alter basal levels of IFN-mRNA expression at
the time of Hendra virus infection (Fig. 4C). To demonstrate that
HeLa cells were capable of upregulating IFN-mRNA in response
to appropriate stimuli, cells were also transfected with poly(I·C)
for 8 h, resulting in significant IFN- upregulation. We detected
no significant change in the viability of cells transfected with these
siRNAs, compared to those in the negative control (Fig. 4D). As a
positive control in this experiment, cells were also transfectedwith
a siRNA targeting polo-like kinase 1(PLK), a gene with an estab-
lished role in regulation of apoptosis (27). RNAi-mediated silenc-
ing of PLK1 caused a significant reduction in HeLa cell viability.
Levels of IRAK2 and TRAF6 mRNA were not significantly altered
in HeLa cells by Hendra virus infection (Fig. 4E).
IRAK2 and TRAF6 are members of the NF-B transduction
pathway. The effect of downregulating these genes on Hendra
virus replication (Fig. 4B) led us to speculate that NF-B activa-
tion followingHendra virus infection could in fact be beneficial to
the virus. As such, we analyzed predicted targets of miR-146a pre-
viously involved in the repression of NF-B signaling, under the ra-
tionale that miR-146a induction would repress them and thereby
potentiate NF-B signaling. Ring finger protein (RNF)11, which is
part of the A20 ubiquitin editing complex (28), was predicted to be
targeted bymiR-146a in horse, human, andmouse (Fig. 5A).
To determine whether miR-146a inhibits translation of
RNF11, the 3= UTR of RNF11 (22), in addition to the 3= UTR
regions of IRAK2 (a validated miR-146a target gene) and F-box
and leucine-rich repeat protein 11 (Fbxl11, not an miR-146a tar-
get gene), was cloned downstream of the Renilla luciferase re-
porter gene. Cells expressing 3= UTR reporter constructs were
transfected with a synthetic miR-146a mimic, and reporter ex-
pression was measured 24 h later by luminescence. miR-146a
caused a significant decrease in RNF11 expression (Fig. 5B), com-
parable to miR-146a-mediated downregulation of IRAK2, the
positive control in this experiment. In contrast, miR-146a did not
influence expression levels of Fbxl11. We next tested the effect of
miR-146a on RNF11 mRNA levels in HeLa cells. HeLa cells were
either infected with Hendra virus or transfected with synthetic
miR-146a for 24 h to induce miR-146a, and RNF11 mRNA levels
were measured by qRT-PCR. Both Hendra virus infection and
miR-146a transfection resulted in small decreases in RNF11
mRNA levels (Fig. 5C and D, respectively) that were not statisti-
cally significant, suggesting that the effect of miR-146a on RNF11
may be exerted at the posttranscriptional level.
We then tested whether modulation of RNF11 impacted Hen-
dra virus replication. First, it was demonstrated that siRNA-me-
diated silencing of RNF11 reduced RNF11 mRNA levels by more
than 80% in HeLa cells (Fig. 5E). Second, the impact of reducing
RNF11 levels on Hendra virus replication was tested. Compared
to cells transfected with a negative-control siRNA, Hendra virus
replication was significantly elevated in cells with reduced RNF11
(Fig. 5F). We also measured the impact of overexpressing RNF11
on Hendra virus replication. Cells overexpressing RNF11 showed
a significant reduction in Hendra virus titers compared to control
cells (Fig. 5G). Collectively, these results suggest that RNF11 is a
FIG 3 miR-146a promotes Hendra virus replication. (A) miR-146a levels in HeLa cells 6 h posttransfection with poly(I·C) (1 g/ml), in untreated HeLa cells
(mock, white bar), or in HeLa cells treated for 16 h with a negative-control miRNA inhibitor (amoNEG, 200 nM, gray bar) or an miR-146a-specific inhibitor
(amo146a, 200 nM, black bar). **, P	 0.05; N.S., not significant. (B)miR-146a levels in HeLa cells 24 h postinfection withHendra virus (MOI, 0.1) in treatment
groups identical to those described for panel A. (C) Hendra virus titers in HeLa cell supernatants of cells treated as in panel A and infected with Hendra virus for
24 h. (D) Hendra virus genome detected by qRT-PCR in HeLa cells treated as in panel A, followed by Hendra virus infection (MOI, 0.1 for 24 h).
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restriction factor of Hendra virus replication and that Hendra
virus makes use of miR-146a induction to decrease RNF11 levels
and favor its replication.
These results suggested thatmodulation ofNF-B activitymay
impactHendra virus replication.We tested the impact of blocking
NF-B activity on Hendra virus replication in two ways. First,
HeLa cells were transfected with the IB superrepressor gene,
which sequesters NF-B in an inactive conformation (23). Upon
infectionwithHendra virus, virus titers were significantly reduced
in HeLa cells expressing the IB superrepressor compared to con-
trol cells (Fig. 6A). We next measured Hendra virus replication in
cells treated with two chemical compound inhibitors of NF-B
activity, Bay11-7082 (29) andMG-132, which also inhibits the 26S
proteosome (30). Hendra virus replication was significantly re-
duced by MG-132 and reduced (not significantly) by Bay11-7082
(Fig. 6B). At these concentrations, Bay11-7082 andMG-132 were
not adversely impacting HeLa cell viability (Fig. 6C), suggesting
that inhibition of Hendra virus replication by MG-132 was not
due to toxicity. Both chemical compounds (Fig. 6D) and the IB
superrepressor (Fig. 6E) significantly inhibited NF-B activity in
HeLa cells. Furthermore, increasing levels of miR-146a in HeLa
cells, by intracellular transfection of an miR-146a mimic, signifi-
cantly increased NF-B activity in HeLa cells, compared to that in
cells transfected with a negative-control miRNA mimic (Fig. 6F).
Collectively these results suggest that Hendra virus replication is
favored by increased NF-B activity.
DISCUSSION
We have shown that miR-146a promotes replication of Hendra
virus. While miR-146a has previously been shown to promote
replication of two other viruses—VSV (14) andEpstein-Barr virus
(13)—the mechanisms of proviral miR-146a activities differ. In
FIG 4 Downregulation of IRAK2 and TRAF6 suppresses Hendra virus replication. (A) IRAK1, IRAK2, and TRAF6 mRNA levels in HeLa cells 48 h posttrans-
fection with siRNAs (40 nM). **, P	 0.01; *, P	 0.05. (B) Virus titers from HeLa cells transfected with siRNAs (40 nM) for 48 h, followed by infection with
Hendra virus (MOI, 0.1) for 24 h. Mock refers to untreated cells. *, P	 0.05 compared to mock samples. N.S., not significant. (C) IFN-mRNA levels in HeLa
cells 48 h posttransfection with siRNAs (40 nM) or poly(I·C) (1.6 g/ml, 8 h posttransfection). *, P	 0.05 compared to siNEG. (D) Viability of HeLa cells 48 h
posttransfection with siRNAs (40 nM). *, P	 0.05 compared to siNEG. (E) IRAK2 and TRAF6 mRNA levels in HeLa cells not infected (white bars) or infected
(black bars) with HeV (MOI, 0.1) for 24 h.
miRNA-146a Promotes Hendra Virus Replication
April 2013 Volume 87 Number 7 jvi.asm.org 3787
the previous two studies, miR-146a downregulated IRAK1,
IRAK2, and TRAF6; this, in turn, impacted type I IFN production
and virus replication.However, human cells infectedwithHendra
virus do not upregulate expression of the type I IFN cytokines
(31). Antagonism of IFN signaling by paramyxoviruses has been
demonstrated in several studies. The Nipah virus phosphoprotein
(P) binds and inhibits STAT1 (32), which would be expected to
block interferon-stimulated gene (ISG) production following
IFN-dependent activation of the IFN-/ receptor. Furthermore,
nuclear translocation of the Nipah W protein inhibits phosphor-
ylation and activation of IFN regulatory factor 3 (IRF-3) (33).
Hendra virus and Nipah virus inhibit these pathways in infected
cells (31). The apparent lack of a type I IFN response to Hendra
virus would suggest that proviral properties ofmiR-146a observed
in the present study are not related to regulation of the type I IFN
response.
Rather, we are proposing a unique context whereby miR-146a
acts in a proinflammatorymanner to aidHendra virus replication.
In a prototypic antiviral immune response, RIG-I activation
prompts activation and nuclear translocation of the three tran-
scription factors required for type I IFN production—NF-B,
IRF3/7, and AP-1 (reviewed in reference 34). The transient pro-
duction of type I IFN is regulated in part by the deubiquitinating
complex A20, induced byNF-B and type I IFN, which feeds back
to inhibit the interaction of RIG-I with themitochondrial adaptor
protein MAVS (34), leading to the termination of NF-B and
IRF3/7 activation.
We hypothesize that Hendra virus modifies the type I IFN
pathway to aid its replication cycle. First, as mentioned above,
Hendra virus blocks type I IFN production. Consistent with these
published reports, HeLa cells infected with Hendra virus did not
upregulate IFN- at 3 h or 8 h postinfection (data not shown).
FIG 5 miR-146a targeting of RNF11 promotes Hendra virus replication. (A) Alignment of miR-146a sequence with the prospective miR-146a binding site in
human, mouse, and horse RNF 3= UTRs. (B) Levels of RNF11, Fxbl11, and IRAK2 3= UTR-luciferase expression in HEK 293T cells transfected with miR-146a.
*, P	 0.05; N.S., not significant. (C) RNF11mRNA levels in HeLa cells not infected () or infected () with HeV (MOI, 0.1) for 24 h. (D) RNF11mRNA levels
in HeLa cells transfected with a negative-control miRNAmimic () or miR-146a mimic () (both 200 nM) for 24 h. (E) RNF11 mRNA levels in HeLa cells 48
h posttransfection with siRNAs (40 nM). (F) Virus titers fromHeLa cells transfected with siRNAs (40 nM, 48 h) followed byHeV infection (MOI, 0.1, 24 h). (G)
Virus titers from HeLa cells transfected with 1.6 g/ml pCMV (vector) or 1.6 g/ml vector containing RNF11 for 24 h, followed by infection with HeV (MOI,
0.1, 24 h).
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However, despite an absence of type I IFN production during
Hendra virus infection, part of the type I IFN signaling pathway
remains active, as illustrated by the RIG-I-dependent induction of
the NF-B-responsive miR-146a.
miR-146a inhibits translation of RNF11, a member of the A20
complex that is required for suppression of NF-B activity (35).
We therefore hypothesize that miR-146a aids Hendra virus repli-
cation by impacting the timing and transient nature of NF-B
regulation by the A20 complex. Our results are therefore sugges-
tive of proinflammatory properties for miR-146a to accompany
previously described anti-inflammatory properties (11, 12, 36).
How NF-B activity positively regulates Hendra virus replica-
tion will be the focus of future work. Increased NF-B activity has
been observed for other paramyxovirus infections. Sendai virus
induces activity of the IB kinase (IKK) complex that phosphor-
ylates and activates the latent NF-B/IB complex (37), while re-
spiratory syncytial virus infection results in persistent NF-B ac-
tivation and downstream interleukin-8 production in lung epi-
thelial cells (38). NF-B activity is associated with both negative
and positive regulation of apoptosis in virally infected cells. NF-B
activity inducedbyhepatitisCvirus, encephalomyocarditis virus, and
Epstein-Barr virus blocks apoptosis (39–41), while conversely, apop-
tosis of dengue virus-infected cells is promoted by NF-B activity
(42). NF-B activity can also have a more direct impact on virus
replication, as observed forHIV-1,which relies onNF-Bactivity for
viral gene expression during monocyte differentiation due to the
presence of B binding sites in the HIV promoter (43).
WhethermiR-146a-mediated regulation ofNF-B activity im-
pacts the replication of viruses other than Hendra virus is also of
interest. A genome-wide microRNA agonist-antagonist screen
demonstrates that miR-146a promotes the replication of murine
gamma herpesvirus 68 in mouse fibroblast cells (44). Further-
FIG 6 Inhibition of NF-B activity suppresses Hendra virus replication. (A) HeV titers from HeLa cells transfected with 1.6 g/ml pCMV-MAD-3 (vector) or
1.6g/ml vector containing IB and infectedwithHeV (24 h) **, P	 0.01; *, P	 0.05. (B)HeV titers fromHeLa cells pretreated for 1 hwith Bay11-7082 (1M)
or MG-132 (10 mM) or appropriate diluent, followed by HeV infection for 24 h (MOI, 0.1). N.S., not significant. (C) Viability of HeLa cells treated with
Bay11-7082 (1 M) or MG-132 (10 mM) for 25 h. Mock refers to untreated cells. (D) Relative NF-B activity in HeLa cells treated for 6 h with Bay 11-7082 (1
M, white bars) or MG-132 (10 mM, black bars) or appropriate diluent. (E) Relative NF-B activity in HeLa cells 24 h posttransfection with IB as in panel A.
(F) Relative NF-B activity in HeLa cells 24 h posttransfection with negative-control miRNA mimic or miR-146a mimic (both 200 nM).
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more, our own preliminary results show that herpes simplex vi-
rus-1 (HSV-1) replication is positively regulated by miR-146a in
HeLa cells (data not shown). As HSV-1 gene expression is regu-
lated by NF-B (45), the data from our study and others are sug-
gestive of a role for miR-146a in the replication of viruses associ-
ated with NF-B activity.
The kinetics of miR-146a induction during Hendra virus in-
fection are intriguing compared to other viral stimuli. In mouse
peritoneal macrophages infected with VSV, miR-146a levels are
most elevated 36 hpostinfection andnot to the extent observed for
Hendra virus. The rapid induction of miR-146a by Hendra virus
in HeLa cells resembles more the rapid induction observed upon
LPS stimulation of THP-1 macrophages (12). This difference be-
tweenHendra virus and VSVmay be explained by the high patho-
genicity of Hendra virus or the high MOI used in this study. An-
other interesting result is the relative decrease in miR-146a levels
observed after maximum induction by Hendra virus, observed
here in vitro and in vivo. Given the known stability of miRNAs
(46), including in serum (47), this result is intriguing and would
suggest that some othermechanism, such as degradation or secre-
tion,may occur aftermiR-146a production. The cellular export of
miRNAs via exosomes (48)may explain the presence ofmiR-146a
in the blood of infected horses and ferrets.
miRNA expression profiles are emerging as tools to assist clin-
ical diagnoses, including those of viral infections (49, 50). For
diagnostic decision support,miRNAs are attractive for several rea-
sons: they can be detected from easily collected bodily fluids such
as blood and urine, are stable once secreted into bodily fluids, and
can be detected using common laboratory techniques such as PCR
(51). Horses infected with Hendra virus do not display signs of
illness (for example, elevated heart rate, temperature) or detect-
able Hendra virus genome in most biological samples until the
onset of florid disease, which can be up to 16 days postexposure
(15). However, during the incubation period, horses replicate vi-
rus in the upper respiratory tract as early as day 2 postexposure
(15). At this time these horses represent a severe risk to humans,
with one reported human case most likely having received expo-
sure during this period (52). A finding of major significance from
the present study is that levels of miR-146a increased during early
stages of virus exposure in horses and ferrets, suggesting thatmea-
suring miRNA levels could assist the early detection of Hendra
virus infection in humans and in horses. However, as it is well
established that miR-146a induction is not unique to Hendra vi-
rus (12–14), a genome-wide analysis of miRNAs responsive to
Hendra virus in vivo would be required to assess miRNAs as tools
to aid the definitive diagnosis of Hendra virus disease.
This study exemplifies how rational analysis of miRNA targets
presents novel avenues in the characterization of cellular factors
aiding in viral replication. It also presents novel opportunities for
treatment and diagnosis of particular virus diseases. Targeting of
RNF11 could present novel therapeutic opportunities against
Hendra virus infections, while miRNA profiling may aid in the
confirmation of Hendra virus disease.
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